Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:59 2025-02-14 EST			5-day change	1st Jan Change
95.37 ^CHF	-2.46%		-1.51%	+7.52%

02-13	European companies cut jobs as economy slows	RE
02-13	Novartis Faces 'Sharp Deceleration' in Growth in Mid-2025, UBS Says	MT

Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint

December 30, 2024 at 01:43 am

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Novartis AG

European companies cut jobs as economy slows	02-13	RE
Novartis Faces 'Sharp Deceleration' in Growth in Mid-2025, UBS Says	02-13	MT
Novartis: Fabhalta tablet approved for HPN in Canada	02-13	CF
Novartis: share price falls, UBS no longer buy	02-13	CF
Novartis Receives Health Canada Approval For Fabhalta Oral Treatment For Adult Patients With PNH	02-13	RE
NOVARTIS AG : UBS lowers his opinion and switches to Neutral	02-13	ZD
NOVARTIS AG : Gets a Buy rating from Deutsche Bank	02-12	ZD
Morgan Stanley Restarts Novartis Coverage at Underweight	02-12	MT
PRESS DIGEST-Financial Times - February 12	02-11	RE
Health Care Down After Humana Earnings -- Health Care Roundup	02-11	DJ
Sector Update: Health Care Stocks Fall in Late Afternoon Trading	02-11	MT
Sector Update: Health Care Stocks Softer Tuesday Afternoon	02-11	MT
Sector Update: Health Care	02-11	MT
Swiss Equities Close Higher; All Eyes on Fresh US Tariffs	02-11	MT
Top Midday Stories: Apple, Alibaba Shares Rise on AI Partnership News; Fidelity National Shares Fall After Q4 Revenue Miss	02-11	MT
Deals of the day-Mergers and acquisitions	02-11	RE
NOVARTIS AG : Gets a Neutral rating from Goldman Sachs	02-11	ZD
Novartis Strikes Up to $3.1 Billion Deal to Buy Anthos Therapeutics	02-11	MT
Novartis to Acquire Anthos Therapeutics for Up to $3.1 Billion	02-11	MT
Novartis: acquisition of Anthos Therapeutics	02-11	CF
Novartis to Buy Cardiovascular Disease-focused Anthos Therapeutics	02-11	MT
Novartis to Buy Anthos Therapeutics for Up to $3.08 Billion	02-11	DJ
Novartis agrees to acquire Anthos for up to $3.1 billion	02-11	RE
Novartis agrees to acquire Anthos for up to $3.1 billion	02-11	RE
Novartis to Buy Cardiovascular Disease-focused Anthos Therapeutics	02-11	MT

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (29.3%); - immunology (18.5%); - cardiovascular, renal and metabolic diseases (17%); - neuroscience (9.4%). The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products. At the end of 2024, Novartis AG had over 30 production sites worldwide. Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).

Employees

75,883

Sector

Pharmaceuticals

Calendar

2025-03-03 - TD Cowen Healthcare Conference

More about the company